Business Context and Reporting Period
This Form 8-K Current Report is filed by Harvard Bioscience, Inc. (HBIO) on April 10, 2025. The filing addresses two primary events: a notice of non-compliance with Nasdaq listing standards regarding minimum bid price and significant changes to the company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of an interim replacement.
Key Financial Metrics and Liquidity
This filing does not contain audited financial statements, revenue, profit, or cash flow data. However, it references specific financial obligations and compensation arrangements:
- Debt Obligations: The company has an existing term loan and senior revolving credit facility. Repayment of this indebtedness is a condition for a performance bonus for the new Interim CFO.
- Stock Price: The company's common stock failed to maintain the required minimum bid price of $1.00 per share for 30 consecutive business days (February 21, 2025, to April 3, 2025).
- Executive Compensation: The new Interim CFO has been granted an annual base salary of $320,000, a potential cash bonus of $50,000, and 100,000 restricted stock units (RSUs).
Material Changes Versus Prior Period
The filing highlights two material changes from the prior status quo:
- Listing Status: The company received a Notification Letter from Nasdaq on April 4, 2025, stating it is not in compliance with Listing Rule 5450(a)(1) due to the low bid price. While not immediately delisted, the company is now in a compliance period.
- Leadership Transition: Jennifer Cote resigned as Chief Financial Officer and Treasurer. Her resignation is effective upon the filing of the Q1 2025 Form 10-Q (expected by May 12, 2025). Mark Frost was appointed as Interim CFO and Treasurer effective immediately upon Ms. Cote's departure.
Guidance, Outlook, Risks, and Contingencies
Compliance Timeline and Risks:
- The company has 180 calendar days (until October 1, 2025) to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days.
- If compliance is not met by the deadline, the company may be eligible to transfer to the Nasdaq Capital Market for an additional 180-day period, provided it meets other listing standards. This may require a reverse stock split.
- Failure to cure the deficiency or qualify for a transfer could result in delisting. An appeal process exists, but success is not assured.
Management Commentary:
- Ms. Cote's resignation is stated to be unrelated to any disagreement with the company regarding financial policies or procedures.
- Mr. Frost brings over 30 years of financial experience, including previous CFO roles at Fathom, Argon Medical Devices, and several public healthcare companies.
Investor Verification Checklist
- Verify the current trading price of HBIO stock to assess the likelihood of meeting the $1.00 bid price requirement within the 180-day window.
- Monitor the upcoming Form 10-Q filing (due by May 12, 2025) for the official effective date of the CFO transition and updated financial position.
- Review the company's debt maturity schedule and liquidity position to evaluate the feasibility of the $50,000 performance bonus tied to debt repayment.
- Watch for any announcements regarding a potential reverse stock split if the company fails to regain compliance by October 1, 2025.